FNDC5 and hydrops fetalis: Overall, irisin deserves to be evaluated as a promising circulating biomarker with a potential additive predictive ability for HF, regardless of its phenotype, perhaps allowing the stratification of T2DM patients at risk without additional costs and the corresponding high expenditure of medical resources.